{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:07:59Z","timestamp":1762506479497,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:p>Brimonidine gel (Mirvaso\u2014Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.<\/jats:p>","DOI":"10.1136\/dtb.2014.12.0295","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T03:47:54Z","timestamp":1418269674000},"page":"138-140","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Brimonidine for erythema caused by rosacea"],"prefix":"10.1136","volume":"52","member":"239","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"key":"2025082722135367000_52.12.138.1","unstructured":"Mirvaso 3mg\/g Gel. Summary of product characteristics, EU. Galderma International, February 2014."},{"key":"2025082722135367000_52.12.138.2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2133.2012.11037.x","article-title":"A study on the epidemiology of rosacea in the UK","volume":"167","author":"Spoendlin","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025082722135367000_52.12.138.3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13671-014-0070-5","article-title":"Updates in rosacea: epidemiology, risk factors, and management strategies","volume":"3","author":"Okhovat","year":"2014","journal-title":"Curr Derm Rep"},{"key":"2025082722135367000_52.12.138.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042829"},{"key":"2025082722135367000_52.12.138.5","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"2025082722135367000_52.12.138.6","unstructured":"Primary Care Dermatology Society, 2014. Rosacea [online]. Available: http:\/\/www.pcds.org.uk\/clinical-guidance\/rosacea [Accessed 12 November 2014]."},{"key":"2025082722135367000_52.12.138.7","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ , et al . Interventions for rosacea. Cochrane Database Syst Rev 2011; 3: CD003262. DOI:10.1002\/14651858.CD003262.pub4 [Last assessed as up-to-date 8 February 2011].","DOI":"10.1002\/14651858.CD003262.pub4"},{"key":"2025082722135367000_52.12.138.8","unstructured":"National Institute for Health and Care Excellence, 2012. Clinical knowledge summaries: rosacea [online]. Available: http:\/\/cks.nice.org.uk\/rosacea [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.9","unstructured":"The Pharmaceutical Press, 2014. Martindale: the complete drug reference [online]. Available: https:\/\/www.medicinescomplete.com\/mc\/martindale\/current\/index.htm [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.10","unstructured":"European Medicines Agency, 2013. Assessment report. Mirvaso [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002642\/WC500163196.pdf [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.11","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2025082722135367000_52.12.138.12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2014.05.044","article-title":"Reliability of Clinician Erythema Assessment grading scale","volume":"71","author":"Tan","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025082722135367000_52.12.138.13","first-page":"699","article-title":"Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea","volume":"13","author":"Jackson","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082722135367000_52.12.138.14","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082722135367000_52.12.138.15","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.jaad.2014.01.853","article-title":"Brimonidine effective but may lead to significant rebound erythema","volume":"70","author":"Ikovitch","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025082722135367000_52.12.138.16","unstructured":"C+D Data, 2014. Mirvaso [online]. Available: http:\/\/www.cddata.co.uk\/Index\/index [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.17","unstructured":"National Institute for Health and Care Excellence, 2014. Facial erythema of rosacea: brimonidine tartrate gel (ESNM43) [online]. Available: http:\/\/www.nice.org.uk\/advice\/esnm43 [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.18","unstructured":"All Wales Medicines Strategy Group, 2014. Brimonidine (Mirvaso) [online]. Available: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/2168 [Accessed 19 November 2014]."},{"key":"2025082722135367000_52.12.138.19","unstructured":"Scottish Medicines Consortium, 2014. Forthcoming submission: brimonidine 0.33% gel (Mirvaso) [online]. Available: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Forthcoming_Submissions\/brimonidine_Mirvaso [Accessed 19 November 2014]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2014.12.0295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:14:06Z","timestamp":1756358046000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2014.12.0295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,11]]},"published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1136\/dtb.2014.12.0295"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2014.12.0295","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}